IFN alpha Monoclonal Antibody (MMHA-2), Invitrogen™

Description

• Specificity: Neutralizes human interferon alpha; binds to human IFN alpha with high affinity (Ka=10^9 M^-1)
• Activity: Interferon was titrated with the use of the cytopathic effect inhibition assay, where 1 unit/mL of interferon was necessary to produce an endpoint of 50%
• One neutralization unit is defined as the amount of serum required to neutralize one unit of human IFN alpha to an endpoint of 50%
• Purity is >95%
• Endotoxin level <1 EU/ug
• Store at -20°C for short-term use (less than 6 months)
• For long-term storage, aliquot and store at -70°C or below for retention of full activity
• Refreezing should be done on dry ice or in a dry ice/alcohol bath
• Further dilution of the product should be in buffers containing protein such as 0.1% BSA
• Packaged by and distributed for PBL Assay Science
• IFN alpha (Interferon alpha) is a Type I interferon belonging to a family of structurally related, species-specific proteins exclusive to vertebrates
• The interaction of IFN-alpha with its receptor component result in the activation of a number of signaling pathways which are mainly involved in innate immune response against viral infection
• In humans, the gene for IFN alpha is located on on chromosome 9
• The type I interferons consist of 14 different alpha isoforms (subtypes with slightly different specificities), and single beta, omega, epsilon and kappa isoforms
• Homologous molecules are found in many species, including rats and mice (and most mammals), and have been identified in birds, reptiles and fish species
• IFN alpha is produced primarily by plasmacytoid dendritic cells, is a potent component of the anti-viral innate immune response and modulates adaptive immunity
• Diseases associated with the dysfunction of IFN alpha include Hepatitis C and Hepatitis.